TILL TRANSAKTIONER
Riskkapital | Hälsovård

Hemideina has raised funds via a private placement

Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.

Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.

Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.

“I’d like to extend my thanks to the team for managing the raise, as well as our team. The high-caliber work completed to date has built confidence around our technology with investors and continues to be the key to our success.”

Elizabeth Williams

CEO and co-founder, Hemideina

Prata med transaktionsteamet

Jonathan Tooth

Director
Melbourne, Australien
Oaklins Henslow

Ryan Whitelegg

Managing Director
Melbourne, Australien
Oaklins Henslow

Relaterade transaktioner

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
Hälsovård

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Lär dig mer
Groupe JVS has completed an LBO with Capza and Bpifrance
Riskkapital | TMT

Groupe JVS has completed an LBO with Capza and Bpifrance

The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.

Lär dig mer
Creo Medical Group plc has completed a US$15.7 million equity fundraise
Hälsovård

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.

Lär dig mer